Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Biliary tract cancer (all types), drawn from the whole corpus: 136 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Most patients are diagnosed too late for surgery.
No screening even in high-incidence regions.
Nothing recorded yet.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Resistance to FGFR2 inhibitors within a year.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Resistance atlas · Lines of therapy.
Gallbladder cancer lacks any approved targeted drug.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 25 changes by month →When this page itself was last checked or edited.
HER2-positive (IHC 3+) unresectable locally advanced or metastatic biliary tract cancer after at least one line of systemic treatment; MHRA 19 February 2026, NICE TA1153 published 7 May 2026 with a commercial arrangement
OS 14.
Accelerated approval, previously treated HER2+ (IHC3+) biliary tract cancer (HERIZON-BTC-01)
Locally advanced, unresectable or metastatic biliary tract cancer with gemcitabine and cisplatin; NICE TA944 recommended 10 January 2024 with a commercial arrangement
HER2+ (IHC 3+) unresectable/metastatic biliary tract cancer, previously treated